Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,481,580
  • Shares Outstanding, K 150,555
  • Annual Sales, $ 13,445 M
  • Annual Income, $ 4,001 M
  • 60-Month Beta 0.44
  • Price/Sales 4.29
  • Price/Cash Flow 10.02
  • Price/Book 5.52
Trade BIIB with:

Options Overview

Details
  • Implied Volatility 39.04%
  • Historical Volatility 117.22%
  • IV Percentile 27%
  • IV Rank 11.86%
  • IV High 120.28% on 06/04/21
  • IV Low 28.11% on 08/20/20
  • Put/Call Vol Ratio 0.69
  • Today's Volume 14,565
  • Volume Avg (30-Day) 29,152
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 252,459
  • Open Int (30-Day) 209,545

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 4.60
  • Number of Estimates 29
  • High Estimate 5.82
  • Low Estimate 3.73
  • Prior Year 10.26
  • Growth Rate Est. (year over year) -55.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
264.12 +47.07%
on 06/01/21
468.55 -17.10%
on 06/07/21
+107.43 (+38.23%)
since 05/18/21
3-Month
257.03 +51.13%
on 04/22/21
468.55 -17.10%
on 06/07/21
+126.17 (+48.11%)
since 03/18/21
52-Week
223.25 +73.99%
on 11/09/20
468.55 -17.10%
on 06/07/21
+128.14 (+49.23%)
since 06/18/20

Most Recent Stories

More News
Dow has Worst Week of the Year on Rate Hike Fears

Dow has Worst Week of the Year on Rate Hike Fears

IBB : 158.77 (-0.18%)
IBBQ : 25.07 (-0.36%)
AMGN : 238.68 (-0.86%)
GILD : 66.61 (-0.91%)
MRNA : 199.19 (-1.62%)
BIIB : 388.44 (+1.28%)
SHOP : 1,466.87 (+1.21%)
SWBI : 23.35 (+17.22%)
CUTR : 47.01 (-0.13%)
Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate

Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.

BIIB : 388.44 (+1.28%)
RGEN : 197.34 (-1.15%)
BLPH : 4.09 (-5.54%)
BNTX : 212.42 (-0.83%)
Biogen's Alzheimer's Drug Approval Puts Biotech ETFs in Spotlight

The FDA's approval of the first new drug to treat Alzheimer's disease in about 20 years has attracted investors' attention toward the biotech sector while sparking new controversies.

BIIB : 388.44 (+1.28%)
IBB : 158.77 (-0.18%)
XBI : 133.58 (-0.60%)
BBH : 194.19 (-0.62%)
FBT : 172.93 (-0.06%)
BTEC : 59.01 (-0.76%)
Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug

Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.

NVS : 93.01 (-1.21%)
BIIB : 388.44 (+1.28%)
RHHBY : 47.0800 (-0.86%)
AMGN : 238.68 (-0.86%)
Thinking about trading options or stock in Prothena Corp, CureVac, Centene Corp, AMC, or Biogen?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRTA, CVAC, CNC, AMC, and BIIB.

BIIB : 388.44 (+1.28%)
CVAC : 61.94 (+7.11%)
PRTA : 51.01 (+4.70%)
AMC : 59.26 (-2.42%)
CNC : 71.69 (-3.53%)
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

- Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE), a debilitating autoimmune disease which has limited...

BIIB : 388.44 (+1.28%)
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease

Biogen Inc. (Nasdaq: BIIB) today announced topline results from its Phase 2 TANGO study of gosuranemab (BIIB092), an investigational anti-tau antibody that was being evaluated as a potential treatment...

BIIB : 388.44 (+1.28%)
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

REGN : 537.92 (+0.36%)
GSK : 39.84 (-1.80%)
BIIB : 388.44 (+1.28%)
VRTX : 187.85 (-0.27%)
NVAX : 174.41 (-3.05%)
SAGE : 56.88 (+3.10%)
ITOS : 25.07 (-5.32%)
Should You Buy Biotech ETFs Now?

Biotech stocks are rallying this month; can the trend continue?

BIIB : 388.44 (+1.28%)
AMGN : 238.68 (-0.86%)
GILD : 66.61 (-0.91%)
MRNA : 199.19 (-1.62%)
IBB : 158.77 (-0.18%)
INO : 8.49 (-3.74%)
XBI : 133.58 (-0.60%)
CLOV : 12.04 (-4.14%)
IBBQ : 25.07 (-0.36%)
Sage Stock Declines on Late-Stage Depression Study Data

Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.

BIIB : 388.44 (+1.28%)
NERV : 2.63 (-1.87%)
SAGE : 56.88 (+3.10%)
VTGN : 2.89 (+0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

3rd Resistance Point 401.76
2nd Resistance Point 396.38
1st Resistance Point 392.41
Last Price 388.44
1st Support Level 383.06
2nd Support Level 377.68
3rd Support Level 373.71

See More

52-Week High 468.55
Last Price 388.44
Fibonacci 61.8% 374.85
Fibonacci 50% 345.90
Fibonacci 38.2% 316.95
52-Week Low 223.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar